Nitin Jain

Research interests

Publications

• Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

  The Lancet Haematology · 2022 · 10.1016/s2352-3026(22)00319-2

• Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

  Journal of the National Comprehensive Cancer Network · 2021 · 10.6004/jnccn.2021.0042

• Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

  The Lancet Haematology · 2021 · 10.1016/s2352-3026(21)00192-7

• Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03736

• 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(20)30210-6

• Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

  Haematologica · 2020 · https://doi.org/10.3324/haematol.2020.252569

• Ibrutinib and Venetoclax for First-Line Treatment of CLL

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1900574

• Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

  Journal of Hematology & Oncology · 2019 · 10.1186/s13045-018-0686-1

• Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

  Blood · 2018 · 10.1182/blood-2018-10-879429

• Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

  The Lancet Haematology · 2018 · https://doi.org/10.1016/s2352-3026(18)30176-5

• Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30011-1

• Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

  JAMA Oncology · 2017 · 10.1001/jamaoncol.2017.2380

• Clinical experience with the BCL 2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

  American Journal of Hematology · 2017 · https://doi.org/10.1002/ajh.25000

• Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

  Nature Reviews Clinical Oncology · 2017 · https://doi.org/10.1038/nrclinonc.2017.148

• Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

  Blood · 2017 · 10.1182/blood-2017-05-786566

• Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

  Clinical Lymphoma Myeloma & Leukemia · 2017 · 10.1016/j.clml.2017.08.101

• Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

  Blood · 2016 · 10.1182/blood-2016-09-736686

• Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

  Blood · 2016 · https://doi.org/10.1182/blood-2016-07-726588

• Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

  Blood · 2016 · https://doi.org/10.1182/blood-2015-08-661702

• Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis

  Cancer · 2016 · 10.1002/cncr.30231

• Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens

  Cancer · 2015 · 10.1002/cncr.29566

• Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

  Blood · 2015 · 10.1182/blood-2014-09-603670

• Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00207-7

• Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

  Blood · 2009 · 10.1182/blood-2009-10-246363

• Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays

  Bioinformatics · 2003 · 10.1093/bioinformatics/btg264

Current projects

No projects listed.